Dr. Gary Bogle

Based on preclinical studies with naturally occurring periodontal defects, the addition of doxycycline to the ATRISORB barrier should significantly reduce barrier infections and periodontal pathogens at the surgical site, said Dr. Gary Bogle, associate professor, Department of Periodontics, Loma Linda University.This will likely lead to improved clinical outcomes..

The pivotal trial, being conducted at three universities, will involve approximately 120 patients and is expected to be completed in about 14 months.If cleared by the U.S. Food and Drug Administration (FDA), Block Drug Corporation (Nasdaq NM : BLOCA) will market this product in North America.Atrix will manufacture the product for Block Drug and receive manufacturing margins and royalties on sales.

Gary Bogle
...
Gary Bogle, DDS, MS

Associate Professor, Periodontics

Gary Bogle, DDS, MS

Associate Professor, Periodontics
...
Gary Bogle